# Humana Inc. (HUM)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/HUM/primer

## Business Model

---
ticker: HUM
step: 01
generated: 2026-05-12
source: quick-research
---

### Humana Inc. (HUM) — Business Overview

#### Business Description
Humana is the second-largest Medicare Advantage (MA) insurer in the United States and one of the most senior-focused health-services companies in the S&P 500. The company operates two reporting segments — Insurance (predominantly Medicare Advantage + state Medicaid + military) and CenterWell (a vertically integrated senior-focused care services platform combining primary care, pharmacy, and home health). 83% of Humana's premiums and services revenue come from contracts with the federal government, the highest government concentration of any major US insurer.

#### Revenue Model
- **Insurance segment (~92% of revenue):** Premiums collected from CMS (Centers for Medicare & Medicaid Services) for Medicare Advantage and Medicare Part D enrollment, state Medicaid contracts, and TRICARE (military). MA accounts for ~14% of revenue from individual MA contracts directly.
- **CenterWell segment (~8% of external revenue, ~28% including intersegment):** Three sub-businesses: (1) CenterWell Pharmacy (mail-order PBM for Humana members and external), (2) CenterWell Primary Care (employed senior-focused primary care clinics — 100,600+ patients added in 2025, +25%; serves Medicaid in 13 states), (3) CenterWell Home Solutions (home health services and hospice).

The vertically integrated model is the key strategic distinction: CenterWell captures the medical-loss-ratio (MLR) dollar that would otherwise go to third-party providers, lowering effective cost of care for senior members while creating an alternative growth engine independent of Insurance margin volatility.

#### Products & Services
**Insurance:**
- Individual Medicare Advantage HMO, PPO, Special Needs Plans (SNPs)
- Group Medicare Advantage (employer / retiree)
- Medicare Part D standalone prescription drug plans
- Medicaid managed care (state contracts in 22+ states)
- TRICARE (military) — east region administrator
- Stand-alone dental, vision, life products
- Group commercial health insurance (sub-scale, has been deemphasized)

**CenterWell Healthcare Services:**
- CenterWell Primary Care (employed senior-focused PCP clinics)
- CenterWell Pharmacy (mail-order + specialty pharmacy)
- CenterWell Home Health (acquired Kindred at Home)
- CenterWell Hospice
- CenterWell Senior Primary Care (Medicaid expansion)

#### Customer Base & Go-to-Market
- **Medicare Advantage members (~5.7M):** Senior citizens 65+ (plus dual-eligibles and SNPs); Humana is the #2 MA carrier behind UnitedHealthcare
- **Medicare Part D members:** Stand-alone prescription drug plan participants
- **Medicaid members:** State-contracted managed care across 22+ states
- **TRICARE:** Military families in the East region (federal contract)
- **CenterWell patients:** ~500K+ across primary care, home health, pharmacy
- **Federal customer:** CMS is effectively Humana's largest "customer" — 83% of premiums and services revenue derives from federal contracts

Sales channels: AEP (Annual Enrollment Period) marketing, broker / agent networks, direct-to-consumer, plus group contract sales for employer-retiree plans.

#### Competitive Position
Humana is the second-largest Medicare Advantage insurer with ~5.7M individual MA members (vs. UnitedHealth's ~10M+). The company's competitive moat is narrower and more senior-focused than UnitedHealth's broader UnitedHealthcare + Optum vertical integration. Key competitive advantages: (1) **MA scale + senior-focused brand** — strongest brand recognition among Medicare-age consumers, (2) **CenterWell vertically integrated care** — owns the primary care, pharmacy, and home health channels that drive MA medical-cost-trend management, (3) **AEP marketing engine** — historically the most effective marketing organization for Medicare enrollment, (4) **National county footprint** — operates in 85% of US counties (down from 89%) with material scale advantages. Key challenges: 2025 STAR ratings collapse (only 25% of members in 4-star+ plans, down from 94% in 2024) — a structural revenue headwind hitting 2026 P&L; modest 2026 STAR recovery (14% in 4.5-star+); higher-than-expected MA medical cost trend (utilization persistent in 2024–2025); $1.5–2B+ annual STAR-related revenue impact; UNH vertical integration advantages widening the competitive gap. The MA recovery thesis is the principal driver of HUM's investment narrative.

#### Key Facts
- Founded: 1961
- Headquarters: Louisville, KY
- Employees: ~67,000
- Exchange: NYSE
- Sector / Industry: Health Care / Health Care Plans
- Market Cap: ~$30B (May 2026)
- 2025 individual MA membership: ~5.7M
- 2026 individual MA membership growth target: ~25% YoY
- Operates in 85% of US counties (2026)
- 83% of premiums and services revenue from federal government contracts

## Financial Snapshot

---
ticker: HUM
step: 04
generated: 2026-05-12
source: quick-research
---

### Humana Inc. (HUM) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2022 | FY2023 | FY2024 | FY2025 | YoY (25v24) |
|--------|--------|--------|--------|--------|-------------|
| Revenue | $92.9B | $106.4B | $117.8B | $129.7B | +10.1% |
| GAAP EPS (diluted) | ~$22.40 | $20.00 | $9.98 | $9.84 | -1.4% |
| Adj. EPS (non-GAAP) | $25.20 | $26.09 | $16.21 | ~$17.14 (normalized) | — |
| Net Income | $2.81B | $2.49B | $1.21B | $1.20B | ~flat |
| Medical Loss Ratio (MA) | ~86% | ~87% | ~90%+ | ~91–92% | — |

GAAP EPS collapsed in 2024 driven by higher-than-expected MA medical cost trend and a $541M Q4 2024 loss. 2025 stabilized at low base; the 2026 hit comes from the STAR rating bonus payment cliff.

#### Cash Flow & Balance Sheet (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$3B (compressed by MA margin pressure) |
| Capex | ~$1.0B |
| Free Cash Flow | ~$2B |
| Cash & Investments | ~$22B (regulated insurance reserves dominate) |
| Total Debt | ~$13B |
| Net Cash position varies by year-end working capital |

#### Key Ratios (approximate, May 2026)
- P/E (TTM, GAAP): ~25x — distorted by depressed earnings | EV/EBITDA: ~12x | FCF Yield: ~5–7%
- Revenue Growth (TTM): ~10% | MLR: ~92%+ | Operating Margin: ~1–2% (compressed)
- Trading at deep discount to historical "quality compounder" multiple

#### Membership / Segment Stats (FY2025 / FY2026)
- 2025 individual MA membership: ~5.7M
- 2026 individual MA membership growth target: ~25% YoY
- Operating county footprint: 85% of US counties (down from 89%)
- CenterWell Primary Care patients: +100,600 in 2025 (+25%)
- 2025 STAR ratings: 25% of MA members in 4+ star plans (down from 94% in 2024)
- 2026 STAR ratings: 14% of MA members in 4.5+ star plans (modest improvement from 3% in 2025)

#### Growth Profile
Humana is in the middle of a multi-year cyclical earnings reset:
1. **2024 medical cost trend shock** — MA utilization persisted at elevated levels, compressing MLR
2. **2025 STAR ratings collapse** — Largest drop of any major MA insurer; analyst estimate $1–3B 2026 revenue impact from lost quality bonus payments
3. **2026 EPS guidance ~$9** — vs. peak normalized EPS of ~$26 in 2023; reflects deepest cyclical compression in years
4. **2027–2028 recovery path** — Consensus models EPS recovery to ~$15 in 2027, ~$26 in 2028 IF: (a) medical cost trend normalizes, (b) STAR ratings recover for 2027 bonus year, (c) 5% effective CMS rate increase materializes, (d) county footprint pruning + benefit design discipline holds margins

**Litigation status:** Humana sued HHS over STAR ratings; lost initial challenge, refiled, lost again, currently appealing to 5th Circuit. Any litigation win would create binary upside catalyst.

#### Forward Estimates
**2026 guidance:** "At least $8.89" GAAP EPS / "at least $9.00" adjusted EPS — decline from 2025 due to STAR Ratings headwind net of mitigation. MLR ~92.75% expected. Bull-side scenarios pencil in cyclical recovery + STAR re-rating + CMS rate normalization driving EPS to ~$15 in 2027 and ~$26 in 2028. Bear-side scenarios extend the STAR / medical cost pressure into 2027 with EPS staying below $12 and continued multiple compression.

## Recent Catalysts

---
ticker: HUM
step: 12
generated: 2026-05-12
source: quick-research
---

### Humana Inc. (HUM) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Cyclical earnings recovery from depressed base** — 2025 normalized EPS was ~$17, 2026 compresses to ~$9 under STAR Ratings headwind. Consensus models recovery to ~$15 in 2027 and ~$26 in 2028 as: (1) STAR ratings improve for bonus year 2027, (2) medical cost trend normalizes, (3) CMS 5% effective rate increase reduces depth of benefit cuts. The valuation already prices a worst-case outcome — even partial recovery supports material re-rating, potentially $260–300+ vs current trading.

2. **MA membership growth ~25% in 2026** — Despite STAR headwinds, Humana's customer-led benefit strategy and improved retention are driving ~25% individual MA membership growth in 2026. This volume base sets up earnings power for 2027/2028 when STAR ratings recover and the membership flows through at improved margins.

3. **CenterWell vertically integrated care platform** — CenterWell Primary Care added 100,600 patients in 2025 (+25%), now serves Medicaid in 13 states. The vertically integrated model owns primary care + pharmacy + home health channels that drive medical cost trend management. Long-term, CenterWell could approach UNH-Optum-like margin-resilience by capturing the MLR dollar internally.

4. **STAR ratings litigation optionality + 2027 STAR recovery** — Humana has appealed to the 5th Circuit Court. Even partial favorable ruling could meaningfully reduce the STAR headwind. Separately, the 2026 STAR cycle showed modest improvement (14% in 4.5+ star plans vs. 3% in 2025), suggesting the corrective actions are working — a clean 2027 STAR cycle would unlock material bonus revenue.

#### Bear Case Risks

1. **2026 STAR Ratings headwind is real and large** — Analyst estimates of $1–3B 2026 revenue impact from STAR bonus payment cliff. Approximately 30% of 2026 MA membership growth is concentrated in 3.5-star contracts, delaying STAR recovery. The Q4 2024 $541M loss demonstrated how fast margin compression can occur when STAR + medical cost combine.

2. **Medical cost trend persistence** — MA medical cost trend has outpaced program funding for two years running. If utilization continues at elevated levels through 2026, MLR could rise above the 92.75% guide, deepening MA segment losses below breakeven and compressing free cash flow needed to fund the membership ramp.

3. **Competitive disadvantage vs. UnitedHealth's vertical integration** — UnitedHealthcare + Optum generates a combined $615B+ revenue base with margin resilience Humana cannot match in the medium term. UNH has 78% of MA members in 4+ star plans (vs. Humana's 25%). The widening competitive gap creates structural disadvantage on benefit design, network, and STAR ratings management.

4. **Litigation risk + regulatory exposure** — Humana has lost two consecutive STAR ratings challenges (district court + circuit). 5th Circuit appeal is final domestic step. If lost, no near-term path to recovering bonus revenue except through 2027 STAR cycle improvement. Additionally, Medicare Advantage faces ongoing CMS scrutiny on coding intensity (V28 RADV), prior authorization, and supplemental benefits — all potential overhangs.

#### Upcoming Events
- **Q2 2026 earnings**: Late July 2026 — focus on AEP 2027 marketing strategy, membership trajectory, medical cost trend
- **CMS Advance Notice 2027 (early 2026)**: Rate framework for next bonus year
- **STAR Ratings 2027**: Released October 2026 — most important annual catalyst
- **Q3 2026 earnings**: Late October 2026 — includes STAR Ratings 2027 impact
- **5th Circuit STAR Ratings appellate decision**: Pending
- **CMS final 2027 rate notice**: April 2026

#### Analyst Sentiment
Sell-side consensus is mixed — split between cyclical-recovery bulls and STAR/margin-trend bears. Average 12-month price targets cluster around $260–$300 (vs. current trading near $260). TIKR / bull-case analysts model ~250% potential upside if MA recovery delivers; bear-case analysts see continued multiple compression with EPS staying suppressed. The principal divergence is on the timing of STAR Ratings recovery + medical cost normalization — a "delayed-by-12-months" recovery scenario meaningfully changes the path.

#### Research Date
Generated: 2026-05-12

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/hum
- Full research API: GET /api/v1/research/HUM/memo
- Coverage universe: /stocks